

Product name:	RelB (6I1) Rabbit Monoclonal Antibody
Cat number:	MABN17007
Conjugate:	Unconjugated
Size:	100µL
Clone:	Monoclonal
Concentration:	1mg/ml
Host:	Rabbit
Isotype:	IgG
Immunogen:	A synthetic peptide of human Rel B
Reactivity:	Human, Mouse, Rat
Applications:	WB 1:1000-1:5000, IHC 1:50-1:100, ICC/IF 1:100-1:500, FC 1:50-1:100, IP 1:20-1:50
Molecular Weight:	62kDa
Purification:	Affinity purification
Form:	Liquid
Buffer:	Rabbit IgG in phosphate buffered saline , pH 7.4, 150mM NaCl, 0.02% New type preservative N and 50% glycerol. Store at +4°C short term. Store at -20°C long term. Avoid freeze / thaw cycle.
Storage:	Store at 4°C short term. Aliquot and store at -20°C for 12 months. Avoid freeze/thaw cycles.

Background:

Transcription factors of the nuclear factor κ B (NF- κ B)/Rel family play a pivotal role in inflammatory and immune responses. RelB, which is generally activated by non-canonical signaling, forms heterodimers with either p50 or p52 NF- κ B subunits to regulate transcription. RelB knock out mice have significant impairments toward inflammatory responses and hematopoietic differentiation. NF-kappa-B is a pleiotropic transcription factor which is present in almost all cell types and is involved in many biological processes such as inflammation, immunity, differentiation, cell growth, tumorigenesis and apoptosis. NF-kappa-B is a homo- or heterodimeric complex formed by the Rel-like domain-containing proteins RELA/p65, RELB, NFKB1/p105, NFKB1/p50, REL and NFKB2/p52. The dimers bind at kappa-B sites in the DNA of their target genes and the individual dimers have distinct preferences for different kappa-B sites that they can bind with distinguishable affinity and specificity. Different dimer combinations act as transcriptional activators or repressors, respectively. NF-kappa-B is controlled by various mechanisms of post- translational modification and subcellular compartmentalization as well as by interactions with other cofactors or corepressors. NF-kappa-B complexes are held in the cytoplasm in an inactive state complexed with members of the NF-kappa-B inhibitor (I-kappa-B) family. In a conventional activation pathway, I-kappa-B is phosphorylated by I- kappa-B kinases (IKKs) in response to different activators, subsequently degraded thus liberating the active NF-kappa-B complex which translocates to the nucleus. NF-kappa-B heterodimeric RelB-p50 and RelB-p52 complexes are transcriptional activators. RELB neither associates with DNA nor with RELA/p65 or REL. Stimulates promoter activity in the presence of NFKB2/p49. As a member of the NUPR1/RELB/IER3 survival pathway, may provide pancreatic ductal adenocarcinoma with remarkable resistance to cell stress, such as starvation or gemcitabine treatment. Regulates the circadian clock by repressing the transcriptional activator activity of the CLOCK- ARNTL/BMAL1 heterodimer in a CRY1/CRY2 independent manner. Increased repression of the heterodimer is seen in the presence of NFKB2/p52. Is required for both T and B lymphocyte maturation and function (PubMed:26385063).